NGNE Neurogene Inc
Price (delayed)
$42.11
Market cap
$547.16M
P/E Ratio
1.34
Dividend/share
N/A
EPS
$31.47
Enterprise value
$449.58M
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed
Highlights
NGNE's EPS has soared by 117% YoY
NGNE's equity has soared by 95% YoY but it is down by 9% QoQ
NGNE's debt is up by 25% year-on-year but it is down by 12% since the previous quarter
NGNE's quick ratio is down by 30% YoY and by 18% from the previous quarter
Neurogene's net income has decreased by 15% YoY and by 14% QoQ
Key stats
What are the main financial stats of NGNE
Market
Valuations
Earnings
Shares outstanding
12.99M
Market cap
$547.16M
Enterprise value
$449.58M
Price to book (P/B)
3.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$55.42M
EBITDA
-$50.45M
Free cash flow
-$74.29M
Per share
Balance sheet
Liquidity
EPS
$31.47
Free cash flow per share
-$4.39
Book value per share
$11.94
Revenue per share
$0
TBVPS
$10.61
Total assets
$179.82M
Total liabilities
$24.81M
Debt
$13.79M
Equity
$155.01M
Working capital
$146.08M
Debt to equity
0.09
Current ratio
12.17
Quick ratio
11.8
Net debt/EBITDA
1.93
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.3%
Return on equity
-37.8%
Return on invested capital
-87.4%
Return on capital employed
-33.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NGNE stock price
How has the Neurogene stock price performed over time
Intraday
0.38%
1 week
19.87%
1 month
20.25%
1 year
N/A
YTD
117.29%
QTD
15.72%
Financial performance
How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$77.22M
Net income
-$55.44M
Gross margin
N/A
Net margin
N/A
NGNE's operating income has dropped by 52% year-on-year and by 12% since the previous quarter
Neurogene's net income has decreased by 15% YoY and by 14% QoQ
Growth
What is Neurogene's growth rate over time
Valuation
What is Neurogene stock price valuation
P/E
1.34
P/B
3.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 117% YoY
NGNE's equity has soared by 95% YoY but it is down by 9% QoQ
The stock's price to book (P/B) is 85% more than its 5-year quarterly average of 1.9 and 85% more than its last 4 quarters average of 1.9
Efficiency
How efficient is Neurogene business performance
The ROE has soared by 76% YoY
NGNE's return on assets is up by 28% year-on-year
The company's return on invested capital fell by 14% QoQ and by 13% YoY
Dividends
What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NGNE.
Financial health
How did Neurogene financials performed over time
The total assets has soared by 91% YoY but it has contracted by 8% from the previous quarter
Neurogene's total liabilities has soared by 72% YoY
NGNE's debt is 91% smaller than its equity
NGNE's equity has soared by 95% YoY but it is down by 9% QoQ
Neurogene's debt to equity has decreased by 36% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.